J&J CFO: Not-for-Profit Vaccine Price Likely to End in 2021

The transcript covers Johnson & Johnson's outlook on the second half of the year, addressing the potential impact of the Delta variant on recovery and healthcare readiness. It discusses the company's vaccine profitability strategy, including future pricing and guidance. The efficacy of the vaccine against variants and the development of a booster are also explored. Financial strategies, including handling talc liabilities and opioid litigation, are discussed. Finally, the recall of sunscreen products and its minimal impact on consumer results are addressed.

What is the main concern regarding the Delta variant as discussed in the video?

• It could derail economic recovery.

• It will lead to more elective procedures.

• It might increase vaccine production costs.

• It is not affected by current vaccines.

How does J&J view their financial guidance for the second half of the year?

• They are uncertain about meeting their targets.

• They plan to reduce market expansion efforts.

• They are confident and see potential for better results.

• They expect a decline in all divisions.

What is J&J's stance on making a profit from their COVID-19 vaccine?

• They will start pricing it for profit next year.

• They have already started making a profit.

• They will only profit if a booster is required.

• They plan to keep it not-for-profit indefinitely.

What is the current status of J&J's study on the Delta variant?

• It shows no efficacy against the Delta variant.

• It has been peer-reviewed and published.

• It is a test tube study not yet peer-reviewed.

• It confirms the need for an immediate booster.

What is J&J's approach to potential booster shots for their vaccine?

• They plan to pair it with an MRI booster.

• They believe a booster is unnecessary.

• They are waiting for health officials' guidance.

• They have already developed a booster.

How is J&J handling their talc-related liabilities?

• By admitting to product safety issues.

• By ignoring the lawsuits.

• By considering a spin-off to manage liabilities.

• By settling all cases out of court.

What was J&J's response to the sunscreen recall?

• They increased production of the sunscreen.

• They ignored consumer safety concerns.

• They acted quickly to recall the product.

• They denied any issues with the product.